Pfizer Ducks FCA Suit Over Lipitor Marketing Practices

Law360, New York (November 15, 2012, 5:41 PM EST) -- A New York federal judge on Wednesday threw out an 8-year-old False Claims Act suit from a former Pfizer Inc. medical director claiming the company engaged in off-label marketing of its statin Lipitor, ruling that federal cholesterol guidelines are meant to be advisory rather than restrictive limitations.

In dismissing qui tam plaintiff Jesse Polansky's fifth amended complaint, U.S. District Judge Brian M. Cogan said that the National Cholesterol Education Program guidelines fall within the standard, noncompulsory definition of the term "guidelines." As long as Pfizer is...
To view the full article, register now.




Case Information

Case Title

United States of America et al v. Pfizer, Inc.

Case Number



New York Eastern

Nature of Suit

Other Statutory Actions


Brian M. Cogan

Date Filed

February 19, 2004

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.